Review Article
Androgen Deprivation Therapy/Androgen Receptor Signaling Inhibitor Treatments for Prostate Cancer: Pathophysiology and Review of Effects on Cardiovascular Disease
Abstract
Androgen deprivation therapy is the cornerstone of systemic management for prostate cancer but is associated with multiple adverse effects that must be considered during treatment. These effects occur because of the profound hypogonadism that is induced from lack of testosterone or due to the medications used in the treatment or in combination with androgen receptor signaling inhibitors. This article critically reviews the associations between androgen deprivation therapy, androgen receptor signaling inhibitors, and cardiovascular complications such as prolonged QT interval, atrial fibrillation, heart failure, atherosclerosis, coronary heart disease, venous thromboembolism, and peripheral arterial occlusive disease. These unfavorable outcomes reinforce the need for regular cardiovascular screening of patients undergoing androgen deprivation for the management of prostate cancer.Posted in: Prostate Disorders2
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. National Cancer Institute. Prostate cancer—cancer stat facts. https://seer.cancer.gov/statfacts/html/prost.html. Accessed November 2, 2022.
2. American Cancer Society. Key statistics for prostate cancer | Prostate cancer facts. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html#references. Accessed November 2, 2022.
3. Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgendeprivation therapy for prostate cancer. N Engl J Med 2010;363:1822–1832.
4. Bosco C, Crawley D, Adolfsson J, et al. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PLoS One 2015;10:e0117344.
5. Zhao J, Zhu S, Sun L, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One 2014;9:e107516.
6. Murphy E. Estrogen signaling and cardiovascular disease. Circ Res 2011; 109:687–696.
7. Arnal JF, Fontaine C, Billon-Galés A, et al. Estrogen receptors and endothelium. Arterioscler Thromb Vasc Biol 2010;30:1506–1512.
8. Hu JR, Duncan MS, Morgans AK, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. Arterioscler Thromb Vasc Biol 2020;40:e55–e64.
9. Okwuosa TM, Morgans A, Rhee JW, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: A Scientific Statement from the American Heart Association. Circ Genom Precis Med 2021;14:E000082.
10. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238–244.
11. Lepor H, Shore ND. LHRH agonists for the treatment of prostate cancer: 2012. Rev Urol 2012;14:1–12.
12. Tolis G, Ackman D, Stellos A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA 1982;79:1658–1662.
13. Levine GN, D’Aamico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association. Circulation 2010;121:833–840.
14. Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med 2020;382: 2187–2196.
15. American Cancer Society. Hormone therapy for prostate cancer. https://www.cancer.org/cancer/types/prostate-cancer/treating/hormone-therapy.html. Accessed June 26, 2022.
16. Mongiat-Artus P, Teillac P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5:2171–2179.
17. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102:1531–1538.
18. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate [reprint of 1941 article]. J Urol 2002; 168:9–12.
19. Moul JW. Twenty-five-year evolution of medical hormonal therapy for prostate cancer. BJU Int 2009;103:145–146.
20. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009; 115:2388–2399.
21. Vandenberk B, Vandael E, Robyns T, et al. Which QT correction formulae to use for QT monitoring? J Am Heart Assoc 2016;5:e003264.
22. Stramba-Badiale M, Spagnolo D, Bosi G, et al. Are gender differences in QTc present at birth? MINES Investigators. Multicenter Italian Study on Neonatal Electrocardiography and Sudden Infant Death Syndrome. Am J Cardiol 1995;75:1277–1278.
23. Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992;8: 690–695.
24. Gagliano-Jucá T, Travison TG, Kantoff PW, et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer. J Endocr Soc 2018;2:485–496.
25. Bai CX, Kurokawa J, Tamagawa M, et al. Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation 2005;112: 1701–1710.
26. Bidoggia H, Maciel JP, Capalozza N, et al. Sex differences on the electrocardiographic pattern of cardiac repolarization: possible role of testosterone. Am Heart J 2000;140:678–683.
27. Vink AS, Postema PG. The role of testosterone and gonadotropins in arrhythmogenesis. J Am Heart Assoc 2021;10:1–3.
28. Salem JE, Waintraub X, Courtillot C, et al. Hypogonadism as a reversible cause of torsades de pointes in men. Circulation 2018;138:110–113.
29. Masuda K, Takanari H, Morishima M, et al. Testosterone-mediated upregulation of delayed rectifier potassium channel in cardiomyocytes causes abbreviation of QT intervals in rats. J Physiol Sci 2018;68:759–767.
30. Hasegawa K, Ito H, Kesino K, et al. Impact of medical castration on malignant arrhythmias in patients with prostate cancer. J Am Heart Assoc 2021;10:1–10.
31. Vink AS, Postema PG. The role of testosterone and gonadotropins in arrhythmogenesis. J Am Heart Assoc 2021;10:e020300.
32. Moss AJ, Kass RS. Long QT syndrome: from channels to cardiac arrhythmias. J Clin Invest 2005;115:2018–2024.
33. Kirilmaz A, Bolu E, Kilicaslan F, et al. Comparison of electrocardiographic repolarization patterns between hypogonadal males and normal subjects. Ann Noninvas Electrocardiol 2003;8:284–288.
34. Vink AS, Clur SAB, Wilde AAM, et al. Effect of age and gender on the QTcinterval in healthy individuals and patients with the long-QT syndrome. Trends Cardiovasc Med 2018;28:64–75.
35. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138–148.
36. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomized, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983–992.
37. Tazmini K, Frisk M, Lewalle A, et al. Hypokalemia promotes arrhythmia by distinct mechanisms in atrial and ventricular myocytes. Circ Res 2020;126: 889–906.
38. Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352–360.
39. Agarwal M, Canan T, Glover G, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer. Curr Oncol Rep 2019;21:91.
40. Haffner SM, Mykkäinen L, Valdez RA, et al. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993; 77:1610–1615.
41. Frederiksen L, Højlund K, Hougaard DM, et al. Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age (Omaha) 2012;34:145–156.
42. Yu XH, Fu YC, Zhang DW, et al. Foam cells in atherosclerosis. Clin Chim Acta 2013;424:245–252.
43. Kim H, Kim S, Han S, et al. Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study. BMC Public Health 2019;19:1112.
44. InformedHealth.org. Complications of coronary artery disease. https://www.ncbi.nlm.nih.gov/books/NBK355309/. Accessed June 15, 2022.
45. Bizzarri F, Mattia C, Ricci M, et al. Cardiogenic shock as a complication of acute mitral valve regurgitation following posteromedial papillary muscle infarction in the absence of coronary artery disease. J Cardiothorac Surg 2008;3:61.
46. Tivesten Å, Pinthus JH, Clarke N, et al. Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms. Urol Oncol 2015;33:464–475.
47. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448–4456.
48. Schmid M, Sammon JD, Reznor G, et al. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events. BJU Int 2016;118:221–229.
49. Azoulay L, Yin H, Benayoun S, et al. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol 2011;60:1244–1250.
50. Conteduca V, di Lorenzo G, Tartarone A, et al. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Crit Rev Oncol Hematol 2013;86:42–51.
51. Klil-Drori AJ, Yin H, Tagalakis V, et al. Androgen deprivation therapy for prostate cancer and the risk of venous thromboembolism. Eur Urol 2016; 70:56–61.
52. Van Hemelrijck M, Adolfsson J, Garmo H, et al. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol 2010;11:450–458.
53. Lu YC, Huang CY, Yeh HM, et al. Associations between peripheral thromboembolic cascular disease and androgen deprivation therapy in Asian prostate cancer patients. Sci Rep 2019;9:14231.
54. Ng C, Chiu PKF, Yee C, et al. Effect of androgen deprivation therapy on cardiovascular function in Chinese patients with advanced prostate cancer: a prospective cohort study. Sci Rep 2020;10:18060.
55. Bretagne M, Lebrun-Vignes B, Pariente A, et al. Heart failure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study. Arch Cardiovasc Dis 2020;113:9–21.
56. Lopes RD, Higano CS, Slovin SF, et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation 2021;144:1295–1307.
57. Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 2014;65:565–573.
58. Hopmans SN, Duivenvoorden WCM, Werstuck GH, et al. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse. Urol Oncol 2014;32:1126–1134.
59. Margel D, Peer A, Ber Y, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting. J Urol 2019;202:1199–1207.
60. George G, Garmo H, Scailteux LM, et al. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: real-world evidence from five databases. Int J Cancer 2021;148:2203–2211.
61. Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol 2015;68: 386–396.
62. Herring MJ, Oskui PM, Hale SL, et al. Testosterone and the cardiovascular system: a comprehensive review of the basic science literature. J Am Heart Assoc 2013;2:e000271.
63. Iacovelli R, Ciccarese C, Bria E, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer 2018;16:e645–e653.
64. Di Nunno V, Mollica V, Santoni M, et al. New hormonal agents in patients with nonmetastatic castration-resistant prostate cancer: meta-analysis of efficacy and safety outcomes. Clin Genitourin Cancer 2019;17:e871–e877.
65. Lu-Yao G, Nikita N, Keith SW, et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol 2020;77:158–166.
66. Nanda A, Chen M, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease– induced congestive heart failure or myocardial infarction. JAMA 2009; 302:866–873.
67. Sun L, Parikh RB, Hubbard RA, et al. Assessment and management of cardiovascular risk factors among US veterans with prostate cancer. JAMA Netw Open 2021;4:e210070-e210070.
68. Holmes JA, Anderson RF, Hoffman LG, et al. Cardiovascular preventive care and coordination of care in prostate cancer survivors: a multi-institutional prospective study. Int J Radiat Oncol Biol Phys 2019;103:112–115.
